Future Market Insights
The frequency of invasive fungal infections has dramatically increased in the recent years and has high mortality and morbidity. Accurate and early diagnosis is very important for the appropriate antifungal therapy. Conventional techniques like microbiology, radiological and histological remain the basis of diagnosis but have limited impact on clinical decision making. There is always a need to characterize fungi accurately and quickly, which can be done by mycology immunoassays test. The fungi are parasitic and saprophytic eukaryotic organisms. The diagnostic methods for fungal infections are direct examination, radiology, and fungal culture and non-culture methods. Diabetic patients are more susceptible to infectious diseases such as Cryptococcus, mucocutaneous candidosis and dematiaceous fungal infection. Rapid and accurate diagnosis of these life threatening fungal diseases is of clinical importance. Mycology is concerned with the study of the fungi. Histopathology, microscopy and use of fungal-specific stains plays an important role in the diagnosis of infections.
Fungi cause disease in man by virtue of their allergenicity, toxigenicity or pathogenicity. Mycology immunoassays are used to detect products or host responses to infection.
Mycology Immunoassays testing Market: Drivers and Restraints
The key factor responsible for the growth of mycology immunoassays testing market is increasing aging population and rising prevalence of chronic and infectious diseases and increased variety of reagents and analytical techniques. Innovative new technologies have the potential to meet the needs of both resource-limited and resource-rich clinical environments. Increasing prevalence and severity of fungal infections in the recent years is driving the market growth of the global mycology immunoassays testing market. In addition, the advancement in treatment and medical care the mycology immunoassays market is increasing globally. However, the diagnosis of fungi is challenging because of lack of specificity and sensitivity.
Mycology Immunoassays testing Market: Segmentation
The global mycology immunoassays testing market is segmented on the basis of technology and end user
On the basis of technology the global mycology immunoassay testing market is segmented into
Polymerase Chain Reaction (PCR)
On the basis of end user the global mycology immunoassay testing market is segmented into
Mycology Immunoassays testing Market: Overview
Based on the technology the global mycology immunoassays testing market is segmented into ELISA, rapid tests, ELISPOT and polymerase chain reaction. As The ELISA segment is expected to account for the largest share of the market, owing to expanding use of mycology immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring. Similarly based on the end user the global mycology immunoassays testing market is segmented into hospitals, clinical laboratories, blood banks, research centers and others. The hospitals segment is expected to account for the largest share of the global immunoassay market. Major factors driving the growth of this market are the rising prevalence of chronic diseases and increasing healthcare infrastructure.
Mycology Immunoassays testing Market: Regional Outlook
Region wise, the global mycology immunoassays testing market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East and Africa. North America expected to dominate the global market for mycology immunoassays testing market high adoption of mycology immunoassay tests, wide availability of healthcare, pharmaceutical & biotechnology companies. Similarly, large patient pool in the Asia –Pacific excluding Japan market are expected to boost the growth of the mycology immunoassay testing market market for the hospitals and research centers segments growth in APEJ region over the forecast period.
Mycology Immunoassays testing Market: Key Players
The major key players in global mycology immunoassays testing markets are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens AG, Beckman Coulter, Inc., Ortho-Clinical Diagnostics, Inc., bioMérieux SA, ELITechGroup and MiraVista Diagnostics.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.